Press Room

Today, the House Insurance Committee passed legislation that would increase access to biomarker testing.

The Consumer Financial Protection Bureau (CFPB) released a proposed rule today to lessen the impact of medical debt on an individual’s credit.

Earlier this morning, House Bill 1754 was voted out of the Senate Banking & Insurance Committee. This legislation, which aims to ensure that biomarker testing is covered by Medicaid and all other state-regulated insurance plans when patients need it, now advances to the Senate floor for consideration.

This afternoon, the Pennsylvania State House passed legislation that would ensure biomarker testing is covered by more insurance plans, including Medicaid, when patients need it.

This afternoon, the New York State Senate passed legislation that would eliminate cost-sharing for lung cancer screenings and follow-up tests. Senate Bill 8553-A received bipartisan support for the proposal impacting all payers in New York, including Medicaid.

Today, the American Cancer Society Cancer Action Network was joined by 51 other organizations in a letter asking Congress to swiftly pass the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act.

Dr. Cheasty Anderson has joined the American Cancer Society Cancer Action Network (ACS CAN) as the managing director for the Gulf Coast Region, which includes Alabama, Arkansas, Louisiana, Mississippi, Oklahoma, Tennessee, and Texas. In this role, Anderson will lead ACS CAN’s staff and volunteers in each state as they work to advance legislation and public policies to reduce cancer.

Today, the House Insurance Committee voted to improve Pennsylvanians’ access to biomarker testing, advancing House Bill 1754 out of committee unanimously. Championed by Representatives Kyle Mullins and Minority Leader Bryan Cutler, the proposal would ensure biomarker testing is a covered benefit in Pennsylvania-regulated insurance plans, including Medicaid, when medical and scientific evidence shows it would provide a benefit to patients. Advocates now look to the full House to favorably advance House Bill 1754 to the Senate.

Governor Jared Polis signed SB24-124 into law during a ceremony at the Governor’s Mansion on Monday afternoon, ensuring more Colorado patients with private insurance have coverage for biomarker testing. The American Cancer Society Cancer Action Network (ACS CAN) recognizes the signing of the bill as a positive first step to increasing access to biomarker testing to connect patients with the right treatment at the right time. During Monday’s ceremony, Governor Polis was surrounded by advocates from ACS CAN including cancer survivors, as well as bill sponsors Sen. Dafna Michaelson Jenet, Rep. Anthony Hartsook, and Rep. Monica Duran. 

Gov. Ned Lamont has signed into law S.B. 307 An Act Concerning Medicaid Coverage of Biomarker Testing. This legislation will increase Connecticut Medicaid (HUSKY Health) coverage of biomarker testing, a form of precision medicine that enables patients to receive treatments personalized to their specific disease.